Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Kindred Biosciences, Inc. (KIN)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues | 100.0% | 100.0% | 100.0% | | | | | |
| Cost of goods sold | 11.0% | 13.8% | 16.5% | | | | | |
| Gross profit | 89.0% | 86.2% | 83.5% | | | | | |
| Research and development | 74.2% | 665.2% | 1342.8% | | | | | |
| General and administrative | 52.1% | 891.1% | 1347.9% | | | | | |
| Depreciation | 11.1% | 59.7% | 40.9% | | | | | |
| EBIT | -37.3% | -1470.1% | -2607.1% | | | | | |
| Pre-tax income | -51.7% | -1442.4% | -2527.5% | | | | | |
| Income taxes | 0.0% | 0.0% | 0.0% | | | | | |
| Net income | -51.7% | -1442.4% | -2527.5% | | | | | |
|